Stroke is the second most common cause of death worldwide. The rates of stroke are increasing
in less affluent countries predominantly because of a high prevalence of modifiable risk factors. The Lipid
Association of India (LAI) has provided a risk stratification algorithm for patients with ischaemic stroke
and recommended low density lipoprotein cholesterol (LDL-C) goals for those in a very high risk group
and extreme risk group (category A) of <50 mg/dl (1.3 mmol/l) while the LDL-C goal for extreme risk
group (category B) is ≤30 mg/dl (0.8 mmol/l). High intensity statins are the first-line lipid lowering therapy. Non-statin therapy like ezetimibe and proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors
may be added as an adjunct to statins in patients who do not achieve LDL-C goals statins alone. In acute
ischaemic stroke, high intensity statin therapy improves neurological and functional outcomes regardless of
thrombolytic therapy. Although conflicting data exist regarding increased risk of intracerebral haemorrhage
(ICH) with statin use, the overall benefit risk ratio favors long-term statin therapy necessitating detailed
discussion with the patient. Patients who have statins withdrawn while being on prior statin therapy at the
time of acute ischaemic stroke have worse functional outcomes and increased mortality. LAI recommends
that statins be continued in such patients. In patients presenting with ICH, statins should not be started in
the acute phase but should be continued in patients who are already taking statins. ICH patients, once stable, need risk stratification for atherosclerotic cardiovascular disease (ASCVD).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.